Intravenous Immunoglobulin (IVIg) Markets to 2024: Global Strategic Business Report - Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins - ResearchAndMarkets.com

DUBLIN--()--The "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million.

The report profiles 24 companies including many key and niche players such as:

  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc. (China)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Shire plc (Ireland)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

Key Topics Covered

1. Industry Overview

  • Immunoglobulins to See Steady Growth
  • Intravenous Immunoglobulin
  • A Proliferating Biologic
  • Application Areas
  • A Brief Review
  • Market Outlook
  • Competitive Scenario

2. Market Trends

  • Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
  • Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
  • IVIg - The Mainstay of PI Therapy
  • Subcutaneous IG Formulations Gain Therapeutic Foothold
  • Hyperimmune Globulin
  • Taking IVIg Therapy a Step Ahead
  • Unsuccessful Clinical Trials for Alzheimer's
  • A major Setback for IVIg Market
  • Synthetic Replacements to IVIg Therapy
  • IVIg Therapy
  • Home-based vs. Outpatient Settings
  • Per Capita Consumption Rate Varies Across Countries
  • Favorable Reimbursement and High Usage make US the Largest Consumer
  • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
  • Aging Global Population: Major Opportunity Indicator
  • Improving Healthcare Expenditure to Foster Growth

3. Plasma Proteins - An Overview

4. Therapy Overview

5. Recent Industry Activity

6. Focus on Select Players

7. Global Market Perspective

Total Companies Profiled: 24 (including Divisions/Subsidiaries 32)

  • The United States (11)
  • Canada (2)
  • Japan (1)
  • Europe (8)
    • France (1)
    • Germany (1)
    • The United Kingdom (2)
    • Italy (1)
    • Spain (1)
    • Rest of Europe (2)
  • Asia-Pacific (Excluding Japan) (9)
  • Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/svckxh/intravenous?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs